Research programme: bacterial NAD-dependent DNA ligase inhibitors - AstraZeneca

Drug Profile

Research programme: bacterial NAD-dependent DNA ligase inhibitors - AstraZeneca

Alternative Names: Adenosine antibacterials - AstraZeneca; Antibacterial adenosine analogues - AstraZeneca; Antibacterial imidazole diamides - AstraZeneca

Latest Information Update: 07 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Imidazoles; Ribonucleosides; Small molecules
  • Mechanism of Action DNA repair enzyme inhibitors; Ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 01 Sep 2011 Preclinical development is ongoing in USA
  • 15 Sep 2009 Preclinical trials in Bacterial infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top